The earnings call highlighted strong revenue growth driven by the performance of RUCONEST and Joenja, along with robust financials and cash flow. Despite some nonrecurring expenses and potential delays in patient reclassification, the outlook remains positive with new market opportunities and pipeline advancements.

Company Guidance -

Q3 2025

During the Q2 2025 earnings call, Pharming's CEO, Fabrice Chouraqui, highlighted a strong quarter with total revenues increasing by 26% year-over-year, reaching $80.4 million, and an operating profit of $12.9 million, excluding $2 million in nonrecurring Abliva acquisition-related expenses. The growth was driven by a 28% increase in RUCONEST sales and an acceleration in Joenja patient uptake, with new patients in the first half of 2025 exceeding the total increase for all of 2024. Pharming upgraded its full-year 2025 revenue guidance to $335-$350 million, up from the prior $325-$340 million estimate. Despite a slight increase in operating expenses due to currency impacts and nonrecurring costs, Pharming reported a significant rise in cash and marketable securities, from $108.9 million in Q1 2025 to $130.8 million by the end of Q2 2025, mainly driven by strong operating cash flows. The company also discussed its strategic focus on expanding Joenja's reach through geographic launches and potential pediatric label expansion, alongside the promising development of its pipeline, including KL1333, which has shown positive interim results in a registrational trial.

Strong Revenue Growth

Total revenues grew by 26% in the second quarter of 2025 versus the same quarter last year. The company upgraded its full year 2025 revenue guidance.

RUCONEST and Joenja Performance

RUCONEST achieved a 28% year-on-year growth, and Joenja saw a 15% quarter-on-quarter revenue growth, with significant increase in the number of patients on therapy.

New Market Opportunities

Joenja was launched in the U.K., and the first patients are on commercial therapy. There is expected approval and expansion in markets such as Japan, the EU, and Canada over the next 12 months.

Strong Financials and Cash Flow

Gross profit increased by 27% to $84.2 million. Operating profit improved to $12.9 million from a loss the previous year. Cash and marketable securities increased significantly.

Pipeline Progress

The company has a growing pipeline with potential blockbuster assets and ongoing phase II studies for new indications.

Pharming Group (PHGUF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PHGUF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	0.00 / -	-0.002	―	―	―
Jul 31, 2025	2025 (Q2)	-0.01 / <0.01	-0.002	400.00% (<+0.01)
May 08, 2025	2025 (Q1)	>-0.01 / -0.02	-0.019	-15.79% (>-0.01)
Mar 13, 2025	2024 (Q4)	<0.01 / <0.01	-0.004	225.00% (<+0.01)
Oct 24, 2024	2024 (Q3)	0.00 / >-0.01	0	―
Aug 01, 2024	2024 (Q2)	0.00 / >-0.01	0.001	-300.00% (>-0.01)
May 08, 2024	2024 (Q1)	<0.01 / -0.02	-0.017	-11.76% (>-0.01)
Mar 14, 2024	2023 (Q4)	0.00 / >-0.01	-0.02	80.00% (+0.02)
Oct 26, 2023	2023 (Q3)	-0.01 / 0.00	0.04	―
Aug 03, 2023	2023 (Q2)	-0.01 / <0.01	0.022	-95.45% (-0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PHGUF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$0.98	$0.98	0.00%
May 08, 2025	$0.88	$0.88	0.00%
Mar 13, 2025	$0.79	$0.90	+13.92%
Oct 24, 2024	$0.91	$0.81	-10.99%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pharming Group (PHGUF) report earnings?

Pharming Group (PHGUF) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Pharming Group (PHGUF) earnings time?

Pharming Group (PHGUF) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PHGUF EPS forecast?

PHGUF EPS forecast for the fiscal quarter 2025 (Q3) is 0.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing